Companies / Institutes

MagForce AG

Max-Planck-Straße 3, 12489 Berlin

+49 30 308380-0
+49 30 308380-99

Management

Dr. Ben J. Lipps

Contact

Denise Scharke

Focus

MagForce AG is a pioneer in the area of nanotechnology-based cancer treatment. It is the first company in the world to receive European approval for a medical product using nanoparticles. In Germany, this innovative therapy is available to patients at the NanoTherm™ therapy centers at the Charité-Universitätsmedizin hospital in Berlin, and the university hospitals in Münster and Kiel. Additional therapy centers in Germany are planned.

News

Logo: MagForce AG
MagForce AG Successfully Completes Private Placement of New Shares
Medical device company increases share capital with gross proceeds of approx. EUR 4.7 million
Logo: MagForce AG
MagForce AG and affiliated European clinics support World Brain Tumor Day on 8 June
At virtual events, patients receive advice on treatment approaches with NanoTherm Therapy
MagForce AG announces plans for further NanoTherm Treatment Centre
Therapy for brain tumour patients will also be available in Thuringia
Magnetic liquid for NanoTherm® treatment. Credit: MagForce AG
The aim to provide brain tumor patients with the best care possible
MagForce hosts practice-oriented application training for the use of the NanoTherm therapy system in treating brain tumors and intends to increase the ...
Brain tumor. Credit: Youtube video MagForce AG
MagForce will focus on establishing cancer treatment with NanoTherm™ therapy
Biotech company publishes financial results and operative highlights